Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALFQ Adjuvant in HIV Vaccine A244/B.63521
NCT05423418Phase 1Completed
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Sep 2022
- Primary completion
- Oct 2024
- Modality
- Lipid-based Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ALFQ in human immunodeficiency virus infection (HIV), sponsored by U.S. Army Medical Research and Development Command. Started Sep 2022; status: completed.
02
Drugs
ALFQ
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05423418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05423418.